APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tumor Necrosis Factor Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Research

Tumor Necrosis Factor Inhibitors Industry Research Report 2026

22 December 2025127 pages

Choose your research edition.

Industry ResearchTumor Necrosis Factor Inhibitors Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumor Necrosis Factor Inhibitors Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Tumor Necrosis Factor Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumor Necrosis Factor Inhibitors Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumor Necrosis Factor Inhibitors Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Tumor Necrosis Factor Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Tumor Necrosis Factor Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Tumor Necrosis Factor Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Tumor Necrosis Factor Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Tumor Necrosis Factor Inhibitors include Janssen Biotech, GlaxoSmithKline, Momenta Pharmaceuticals, MedImmune, LG Life Sciences, LEO Pharma, Intas Pharmaceuticals, HanAll Biopharma and EPIRUS Biopharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Tumor Necrosis Factor Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Tumor Necrosis Factor Inhibitors Market by Company

Janssen Biotech

GlaxoSmithKline

Momenta Pharmaceuticals

MedImmune

LG Life Sciences

LEO Pharma

Intas Pharmaceuticals

HanAll Biopharma

EPIRUS Biopharmaceuticals

Dexa Medica

CASI Pharmaceuticals

Bionovis

Tumor Necrosis Factor Inhibitors Segment by Type

Enbrel

Remicade

Humira

Others

Tumor Necrosis Factor Inhibitors Segment by Application

Ischemic Stroke

Parkinson's Diseases

Multiple Sclerosis

Alzheimer's Diseases

Others

Tumor Necrosis Factor Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Tumor Necrosis Factor Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Tumor Necrosis Factor Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Tumor Necrosis Factor Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Tumor Necrosis Factor Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Tumor Necrosis Factor Inhibitors Sales (k units) of Manufacturers (2021-2026) Table 7. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 8. Global Tumor Necrosis Factor Inhibitors Revenue of Manufacturers (2021-2026) Table 9. Global Tumor Necrosis Factor Inhibitors Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Tumor Necrosis Factor Inhibitors Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Tumor Necrosis Factor Inhibitors Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Tumor Necrosis Factor Inhibitors, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Tumor Necrosis Factor Inhibitors, Product Type & Application Table 14. Global Tumor Necrosis Factor Inhibitors Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Tumor Necrosis Factor Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Janssen Biotech Company Information Table 19. Janssen Biotech Business Overview Table 20. Janssen Biotech Tumor Necrosis Factor Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Janssen Biotech Tumor Necrosis Factor Inhibitors Product Portfolio Table 22. Janssen Biotech Recent Developments Table 23. GlaxoSmithKline Company Information Table 24. GlaxoSmithKline Business Overview Table 25. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Product Portfolio Table 27. GlaxoSmithKline Recent Developments Table 28. Momenta Pharmaceuticals Company Information Table 29. Momenta Pharmaceuticals Business Overview Table 30. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Portfolio Table 32. Momenta Pharmaceuticals Recent Developments Table 33. MedImmune Company Information Table 34. MedImmune Business Overview Table 35. MedImmune Tumor Necrosis Factor Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. MedImmune Tumor Necrosis Factor Inhibitors Product Portfolio Table 37. MedImmune Recent Developments Table 38. LG Life Sciences Company Information Table 39. LG Life Sciences Business Overview Table 40. LG Life Sciences Tumor Necrosis Factor Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. LG Life Sciences Tumor Necrosis Factor Inhibitors Product Portfolio Table 42. LG Life Sciences Recent Developments Table 43. LEO Pharma Company Information Table 44. LEO Pharma Business Overview Table 45. LEO Pharma Tumor Necrosis Factor Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. LEO Pharma Tumor Necrosis Factor Inhibitors Product Portfolio Table 47. LEO Pharma Recent Developments Table 48. Intas Pharmaceuticals Company Information Table 49. Intas Pharmaceuticals Business Overview Table 50. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Portfolio Table 52. Intas Pharmaceuticals Recent Developments Table 53. HanAll Biopharma Company Information Table 54. HanAll Biopharma Business Overview Table 55. HanAll Biopharma Tumor Necrosis Factor Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. HanAll Biopharma Tumor Necrosis Factor Inhibitors Product Portfolio Table 57. HanAll Biopharma Recent Developments Table 58. EPIRUS Biopharmaceuticals Company Information Table 59. EPIRUS Biopharmaceuticals Business Overview Table 60. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Product Portfolio Table 62. EPIRUS Biopharmaceuticals Recent Developments Table 63. Dexa Medica Company Information Table 64. Dexa Medica Business Overview Table 65. Dexa Medica Tumor Necrosis Factor Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Dexa Medica Tumor Necrosis Factor Inhibitors Product Portfolio Table 67. Dexa Medica Recent Developments Table 68. CASI Pharmaceuticals Company Information Table 69. CASI Pharmaceuticals Business Overview Table 70. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Portfolio Table 72. CASI Pharmaceuticals Recent Developments Table 73. Bionovis Company Information Table 74. Bionovis Business Overview Table 75. Bionovis Tumor Necrosis Factor Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Bionovis Tumor Necrosis Factor Inhibitors Product Portfolio Table 77. Bionovis Recent Developments Table 78. Global Tumor Necrosis Factor Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 79. Global Tumor Necrosis Factor Inhibitors Sales by Region (2021-2026) & (k units) Table 80. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Region (2021-2026) Table 81. Global Tumor Necrosis Factor Inhibitors Sales by Region (2027-2032) & (k units) Table 82. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Region (2027-2032) Table 83. Global Tumor Necrosis Factor Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 84. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Region (2021-2026) Table 85. Global Tumor Necrosis Factor Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 86. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Region (2027-2032) Table 87. North America Tumor Necrosis Factor Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. North America Tumor Necrosis Factor Inhibitors Sales by Country (2021-2026) & (k units) Table 89. North America Tumor Necrosis Factor Inhibitors Sales by Country (2027-2032) & (k units) Table 90. North America Tumor Necrosis Factor Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 91. North America Tumor Necrosis Factor Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 92. Europe Tumor Necrosis Factor Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Europe Tumor Necrosis Factor Inhibitors Sales by Country (2021-2026) & (k units) Table 94. Europe Tumor Necrosis Factor Inhibitors Sales by Country (2027-2032) & (k units) Table 95. Europe Tumor Necrosis Factor Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 96. Europe Tumor Necrosis Factor Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 97. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Country (2021-2026) & (k units) Table 99. Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Country (2027-2032) & (k units) Table 100. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 101. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 102. South America Tumor Necrosis Factor Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. South America Tumor Necrosis Factor Inhibitors Sales by Country (2021-2026) & (k units) Table 104. South America Tumor Necrosis Factor Inhibitors Sales by Country (2027-2032) & (k units) Table 105. South America Tumor Necrosis Factor Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 106. South America Tumor Necrosis Factor Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 107. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Country (2021-2026) & (k units) Table 109. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Country (2027-2032) & (k units) Table 110. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 111. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 112. Global Tumor Necrosis Factor Inhibitors Sales by Type (2021-2026) & (k units) Table 113. Global Tumor Necrosis Factor Inhibitors Sales by Type (2027-2032) & (k units) Table 114. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2021-2026) Table 115. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2027-2032) Table 116. Global Tumor Necrosis Factor Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 117. Global Tumor Necrosis Factor Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 118. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2021-2026) Table 119. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2027-2032) Table 120. Global Tumor Necrosis Factor Inhibitors Price by Type (2021-2026) & (US$/unit) Table 121. Global Tumor Necrosis Factor Inhibitors Price by Type (2027-2032) & (US$/unit) Table 122. Global Tumor Necrosis Factor Inhibitors Sales by Application (2021-2026) & (k units) Table 123. Global Tumor Necrosis Factor Inhibitors Sales by Application (2027-2032) & (k units) Table 124. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2021-2026) Table 125. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2027-2032) Table 126. Global Tumor Necrosis Factor Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 127. Global Tumor Necrosis Factor Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 128. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2021-2026) Table 129. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2027-2032) Table 130. Global Tumor Necrosis Factor Inhibitors Price by Application (2021-2026) & (US$/unit) Table 131. Global Tumor Necrosis Factor Inhibitors Price by Application (2027-2032) & (US$/unit) Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. Tumor Necrosis Factor Inhibitors Distributors List Table 135. Tumor Necrosis Factor Inhibitors Customers List Table 136. Tumor Necrosis Factor Inhibitors Industry Trends Table 137. Tumor Necrosis Factor Inhibitors Industry Drivers Table 138. Tumor Necrosis Factor Inhibitors Industry Restraints Table 139. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Tumor Necrosis Factor Inhibitors Product Image Figure 5. Global Tumor Necrosis Factor Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Tumor Necrosis Factor Inhibitors Market Size (2021-2032) & (US$ Million) Figure 7. Global Tumor Necrosis Factor Inhibitors Sales (2021-2032) & (k units) Figure 8. Global Tumor Necrosis Factor Inhibitors Average Price (US$/unit) & (2021-2032) Figure 9. Enbrel Product Image Figure 10. Remicade Product Image Figure 11. Humira Product Image Figure 12. Others Product Image Figure 13. Ischemic Stroke Product Image Figure 14. Parkinson's Diseases Product Image Figure 15. Multiple Sclerosis Product Image Figure 16. Alzheimer's Diseases Product Image Figure 17. Others Product Image Figure 18. Global Tumor Necrosis Factor Inhibitors Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Tumor Necrosis Factor Inhibitors, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Tumor Necrosis Factor Inhibitors Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Tumor Necrosis Factor Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Tumor Necrosis Factor Inhibitors Sales by Region in 2025 Figure 24. Global Tumor Necrosis Factor Inhibitors Revenue by Region in 2025 Figure 25. North America Tumor Necrosis Factor Inhibitors Market Size by Country in 2025 Figure 26. North America Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2021-2032) Figure 27. North America Tumor Necrosis Factor Inhibitors Revenue Market Share by Country (2021-2032) Figure 28. United States Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Mexico Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe Tumor Necrosis Factor Inhibitors Market Size by Country in 2025 Figure 32. Europe Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2021-2032) Figure 33. Europe Tumor Necrosis Factor Inhibitors Revenue Market Share by Country (2021-2032) Figure 34. Germany Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Russia Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Spain Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Netherlands Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Switzerland Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Sweden Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Poland Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Asia Pacific Tumor Necrosis Factor Inhibitors Market Size by Country in 2025 Figure 45. Asia Pacific Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2021-2032) Figure 46. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue Market Share by Country (2021-2032) Figure 47. China Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Japan Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South Korea Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. India Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Australia Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Taiwan Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. South America Tumor Necrosis Factor Inhibitors Market Size by Country in 2025 Figure 56. South America Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2021-2032) Figure 57. South America Tumor Necrosis Factor Inhibitors Revenue Market Share by Country (2021-2032) Figure 58. Brazil Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Argentina Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Chile Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa Tumor Necrosis Factor Inhibitors Market Size by Country in 2025 Figure 62. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue Market Share by Country (2021-2032) Figure 64. Egypt Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2021-2032) Figure 70. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2021-2032) Figure 71. Global Tumor Necrosis Factor Inhibitors Price (US$/unit) by Type (2021-2032) Figure 72. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2021-2032) Figure 73. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2021-2032) Figure 74. Global Tumor Necrosis Factor Inhibitors Price (US$/unit) by Application (2021-2032) Figure 75. Tumor Necrosis Factor Inhibitors Value Chain Figure 76. Tumor Necrosis Factor Inhibitors Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Tumor Necrosis Factor Inhibitors Industry Opportunities and Challenges

Scope & coverage.

Types
  • Enbrel
  • Remicade
  • Humira
  • Others
Applications
  • Ischemic Stroke
  • Parkinson's Diseases
  • Multiple Sclerosis
  • Alzheimer's Diseases
  • Others
Companies covered
  • Janssen Biotech
  • GlaxoSmithKline
  • Momenta Pharmaceuticals
  • MedImmune
  • LG Life Sciences
  • LEO Pharma
  • Intas Pharmaceuticals
  • HanAll Biopharma
  • EPIRUS Biopharmaceuticals
  • Dexa Medica
  • CASI Pharmaceuticals
  • Bionovis

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Tumor Necrosis Factor Inhibitors Market Size (2021-2032)
  4. 2.2.2 Global Tumor Necrosis Factor Inhibitors Sales (2021-2032)
  5. 2.2.3 Global Tumor Necrosis Factor Inhibitors Market Average Price (2021-2032)
  6. 2.3 Tumor Necrosis Factor Inhibitors by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Enbrel
  9. 2.3.3 Remicade
  10. 2.3.4 Humira
  11. 2.3.5 Others
  12. 2.4 Tumor Necrosis Factor Inhibitors by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Ischemic Stroke
  15. 2.4.3 Parkinson's Diseases
  16. 2.4.4 Multiple Sclerosis
  17. 2.4.5 Alzheimer's Diseases
  18. 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Tumor Necrosis Factor Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Tumor Necrosis Factor Inhibitors Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Tumor Necrosis Factor Inhibitors Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Tumor Necrosis Factor Inhibitors Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Tumor Necrosis Factor Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Tumor Necrosis Factor Inhibitors, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Tumor Necrosis Factor Inhibitors, Product Type & Application
  8. 3.8 Global Manufacturers of Tumor Necrosis Factor Inhibitors, Established Date
  9. 3.9 Global Tumor Necrosis Factor Inhibitors Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Janssen Biotech
  2. 4.1.1 Janssen Biotech Company Information
  3. 4.1.2 Janssen Biotech Business Overview
  4. 4.1.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Product Portfolio
  6. 4.1.5 Janssen Biotech Recent Developments
  7. 4.2 GlaxoSmithKline
  8. 4.2.1 GlaxoSmithKline Company Information
  9. 4.2.2 GlaxoSmithKline Business Overview
  10. 4.2.3 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Product Portfolio
  12. 4.2.5 GlaxoSmithKline Recent Developments
  13. 4.3 Momenta Pharmaceuticals
  14. 4.3.1 Momenta Pharmaceuticals Company Information
  15. 4.3.2 Momenta Pharmaceuticals Business Overview
  16. 4.3.3 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Portfolio
  18. 4.3.5 Momenta Pharmaceuticals Recent Developments
  19. 4.4 MedImmune
  20. 4.4.1 MedImmune Company Information
  21. 4.4.2 MedImmune Business Overview
  22. 4.4.3 MedImmune Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 MedImmune Tumor Necrosis Factor Inhibitors Product Portfolio
  24. 4.4.5 MedImmune Recent Developments
  25. 4.5 LG Life Sciences
  26. 4.5.1 LG Life Sciences Company Information
  27. 4.5.2 LG Life Sciences Business Overview
  28. 4.5.3 LG Life Sciences Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 LG Life Sciences Tumor Necrosis Factor Inhibitors Product Portfolio
  30. 4.5.5 LG Life Sciences Recent Developments
  31. 4.6 LEO Pharma
  32. 4.6.1 LEO Pharma Company Information
  33. 4.6.2 LEO Pharma Business Overview
  34. 4.6.3 LEO Pharma Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 LEO Pharma Tumor Necrosis Factor Inhibitors Product Portfolio
  36. 4.6.5 LEO Pharma Recent Developments
  37. 4.7 Intas Pharmaceuticals
  38. 4.7.1 Intas Pharmaceuticals Company Information
  39. 4.7.2 Intas Pharmaceuticals Business Overview
  40. 4.7.3 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Portfolio
  42. 4.7.5 Intas Pharmaceuticals Recent Developments
  43. 4.8 HanAll Biopharma
  44. 4.8.1 HanAll Biopharma Company Information
  45. 4.8.2 HanAll Biopharma Business Overview
  46. 4.8.3 HanAll Biopharma Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 HanAll Biopharma Tumor Necrosis Factor Inhibitors Product Portfolio
  48. 4.8.5 HanAll Biopharma Recent Developments
  49. 4.9 EPIRUS Biopharmaceuticals
  50. 4.9.1 EPIRUS Biopharmaceuticals Company Information
  51. 4.9.2 EPIRUS Biopharmaceuticals Business Overview
  52. 4.9.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Product Portfolio
  54. 4.9.5 EPIRUS Biopharmaceuticals Recent Developments
  55. 4.10 Dexa Medica
  56. 4.10.1 Dexa Medica Company Information
  57. 4.10.2 Dexa Medica Business Overview
  58. 4.10.3 Dexa Medica Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Dexa Medica Tumor Necrosis Factor Inhibitors Product Portfolio
  60. 4.10.5 Dexa Medica Recent Developments
  61. 4.11 CASI Pharmaceuticals
  62. 4.11.1 CASI Pharmaceuticals Company Information
  63. 4.11.2 CASI Pharmaceuticals Business Overview
  64. 4.11.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Portfolio
  66. 4.11.5 CASI Pharmaceuticals Recent Developments
  67. 4.12 Bionovis
  68. 4.12.1 Bionovis Company Information
  69. 4.12.2 Bionovis Business Overview
  70. 4.12.3 Bionovis Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Bionovis Tumor Necrosis Factor Inhibitors Product Portfolio
  72. 4.12.5 Bionovis Recent Developments
5 Global Tumor Necrosis Factor Inhibitors Market Scenario by Region
  1. 5.1 Global Tumor Necrosis Factor Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Tumor Necrosis Factor Inhibitors Sales by Region: 2021-2032
  3. 5.2.1 Global Tumor Necrosis Factor Inhibitors Sales by Region: 2021-2026
  4. 5.2.2 Global Tumor Necrosis Factor Inhibitors Sales by Region: 2027-2032
  5. 5.3 Global Tumor Necrosis Factor Inhibitors Revenue by Region: 2021-2032
  6. 5.3.1 Global Tumor Necrosis Factor Inhibitors Revenue by Region: 2021-2026
  7. 5.3.2 Global Tumor Necrosis Factor Inhibitors Revenue by Region: 2027-2032
  8. 5.4 North America Tumor Necrosis Factor Inhibitors Market Facts & Figures by Country
  9. 5.4.1 North America Tumor Necrosis Factor Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Tumor Necrosis Factor Inhibitors Sales by Country (2021-2032)
  11. 5.4.3 North America Tumor Necrosis Factor Inhibitors Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Tumor Necrosis Factor Inhibitors Market Facts & Figures by Country
  16. 5.5.1 Europe Tumor Necrosis Factor Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Tumor Necrosis Factor Inhibitors Sales by Country (2021-2032)
  18. 5.5.3 Europe Tumor Necrosis Factor Inhibitors Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Tumor Necrosis Factor Inhibitors Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Tumor Necrosis Factor Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Tumor Necrosis Factor Inhibitors Market Facts & Figures by Country
  41. 5.7.1 South America Tumor Necrosis Factor Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Tumor Necrosis Factor Inhibitors Sales by Country (2021-2032)
  43. 5.7.3 South America Tumor Necrosis Factor Inhibitors Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Tumor Necrosis Factor Inhibitors Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Tumor Necrosis Factor Inhibitors Sales by Type (2021-2032)
  2. 6.1.1 Global Tumor Necrosis Factor Inhibitors Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2021-2032)
  4. 6.2 Global Tumor Necrosis Factor Inhibitors Revenue by Type (2021-2032)
  5. 6.2.1 Global Tumor Necrosis Factor Inhibitors Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Tumor Necrosis Factor Inhibitors Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Tumor Necrosis Factor Inhibitors Sales by Application (2021-2032)
  2. 7.1.1 Global Tumor Necrosis Factor Inhibitors Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2021-2032)
  4. 7.2 Global Tumor Necrosis Factor Inhibitors Revenue by Application (2021-2032)
  5. 7.2.1 Global Tumor Necrosis Factor Inhibitors Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Tumor Necrosis Factor Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Tumor Necrosis Factor Inhibitors Value Chain Analysis
  2. 8.1.1 Tumor Necrosis Factor Inhibitors Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Tumor Necrosis Factor Inhibitors Production Mode & Process
  5. 8.2 Tumor Necrosis Factor Inhibitors Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Tumor Necrosis Factor Inhibitors Distributors
  8. 8.2.3 Tumor Necrosis Factor Inhibitors Customers
9 Global Tumor Necrosis Factor Inhibitors Analyzing Market Dynamics
  1. 9.1 Tumor Necrosis Factor Inhibitors Industry Trends
  2. 9.2 Tumor Necrosis Factor Inhibitors Industry Drivers
  3. 9.3 Tumor Necrosis Factor Inhibitors Industry Opportunities and Challenges
  4. 9.4 Tumor Necrosis Factor Inhibitors Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst